PL2491037T3 - Pochodne chinazolin-4(3H)-onu stosowane jako inhibitory kinazy PI3 - Google Patents

Pochodne chinazolin-4(3H)-onu stosowane jako inhibitory kinazy PI3

Info

Publication number
PL2491037T3
PL2491037T3 PL10771416T PL10771416T PL2491037T3 PL 2491037 T3 PL2491037 T3 PL 2491037T3 PL 10771416 T PL10771416 T PL 10771416T PL 10771416 T PL10771416 T PL 10771416T PL 2491037 T3 PL2491037 T3 PL 2491037T3
Authority
PL
Poland
Prior art keywords
quinazolin
kinase inhibitors
derivatives used
derivatives
kinase
Prior art date
Application number
PL10771416T
Other languages
English (en)
Inventor
John King-Underwood
Kazuhiro Ito
Peter John Murray
George Hardy
Frederick Arthur Brookfield
Christopher John Brown
Original Assignee
Respivert Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41462531&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2491037(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Respivert Ltd filed Critical Respivert Ltd
Publication of PL2491037T3 publication Critical patent/PL2491037T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
PL10771416T 2009-10-19 2010-10-19 Pochodne chinazolin-4(3H)-onu stosowane jako inhibitory kinazy PI3 PL2491037T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0918249.4A GB0918249D0 (en) 2009-10-19 2009-10-19 Compounds
PCT/EP2010/065746 WO2011048111A1 (en) 2009-10-19 2010-10-19 Compounds
EP10771416.4A EP2491037B1 (en) 2009-10-19 2010-10-19 Quinazolin-4(3h)-one derivatives used as pi3 kinase inhibitors

Publications (1)

Publication Number Publication Date
PL2491037T3 true PL2491037T3 (pl) 2014-09-30

Family

ID=41462531

Family Applications (1)

Application Number Title Priority Date Filing Date
PL10771416T PL2491037T3 (pl) 2009-10-19 2010-10-19 Pochodne chinazolin-4(3H)-onu stosowane jako inhibitory kinazy PI3

Country Status (35)

Country Link
US (4) US8741909B2 (pl)
EP (1) EP2491037B1 (pl)
JP (1) JP5889792B2 (pl)
KR (1) KR101770616B1 (pl)
CN (1) CN102712645B (pl)
AR (1) AR078674A1 (pl)
AU (1) AU2010309832B2 (pl)
BR (1) BR112012009214A2 (pl)
CA (1) CA2777902C (pl)
CL (1) CL2012000981A1 (pl)
CR (1) CR20120264A (pl)
CY (1) CY1116057T1 (pl)
DK (1) DK2491037T3 (pl)
EA (1) EA020330B3 (pl)
EC (1) ECSP12011805A (pl)
ES (1) ES2477270T3 (pl)
GB (1) GB0918249D0 (pl)
HR (1) HRP20140599T1 (pl)
IL (1) IL219248A (pl)
ME (1) ME02064B (pl)
MX (1) MX2012004525A (pl)
MY (1) MY164731A (pl)
NI (2) NI201200061A (pl)
NZ (2) NZ599162A (pl)
PE (1) PE20121390A1 (pl)
PH (1) PH12012500620A1 (pl)
PL (1) PL2491037T3 (pl)
PT (1) PT2491037E (pl)
RS (1) RS53385B (pl)
SI (1) SI2491037T1 (pl)
SM (1) SMT201400086B (pl)
TW (1) TWI478923B (pl)
UA (1) UA108743C2 (pl)
WO (1) WO2011048111A1 (pl)
ZA (1) ZA201203662B (pl)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ586418A (en) 2007-12-19 2012-09-28 Cancer Rec Tech Ltd Pyrido[2,3-b]pyrazine-8-substituted compounds and their use
GB0918249D0 (en) 2009-10-19 2009-12-02 Respivert Ltd Compounds
DK2531502T3 (da) 2010-02-01 2014-05-19 Cancer Rec Tech Ltd 1-(5-tert-butyl-2-phenyl-2h-pyrazol-3-yl)-3-[2-fluoro-4-(1-methyl-2-oxo-2,3-dihydro-1h-imidazo[4,5-b]pyridin-7-yloxy)-phenyl]-urea og associerede forbindelser og ders anvendelse i terapi
UY33337A (es) * 2010-10-18 2011-10-31 Respivert Ltd DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS
ES2661510T3 (es) 2011-12-15 2018-04-02 Novartis Ag Uso de inhibidores de la actividad o función de PI3K
NZ627963A (en) * 2012-03-13 2015-08-28 Respivert Ltd Dry powder pharmaceutical formulations for inhalation of a compound that inhibits pi3 kinase
US8940742B2 (en) 2012-04-10 2015-01-27 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
HK1214159A1 (zh) 2012-11-08 2016-07-22 Rhizen Pharmaceuticals S.A. 含有PDE4抑制剂和PI3δ或双重PI3δ-γ激酶抑制剂的药物组合物
TW201522341A (zh) * 2013-03-15 2015-06-16 Respivert Ltd 化合物
AR095353A1 (es) 2013-03-15 2015-10-07 Respivert Ltd Compuesto
SG11201510064WA (en) 2013-06-14 2016-01-28 Psioxus Theraupeutics Ltd A dosing regime and formulations for type b adenoviruses
EP3964507A1 (en) 2013-10-04 2022-03-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
WO2015051241A1 (en) 2013-10-04 2015-04-09 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
GB201320732D0 (en) 2013-11-25 2014-01-08 Cancer Rec Tech Ltd Methods of chemical synthesis
GB201320729D0 (en) 2013-11-25 2014-01-08 Cancer Rec Tech Ltd Therapeutic compounds and their use
CN106456628A (zh) 2014-03-19 2017-02-22 无限药品股份有限公司 用于治疗PI3K‑γ介导的障碍的杂环化合物
GB201510197D0 (en) 2014-06-12 2015-07-29 Psioxus Therapeutics Ltd Method of treating ovarian cancer
EA201692557A1 (ru) 2014-07-04 2017-05-31 Люпин Лимитед Хинолизиноновые производные в качестве ингибиторов pi3k
WO2016054491A1 (en) 2014-10-03 2016-04-07 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
CN114230571B (zh) 2015-09-14 2025-07-08 无限药品股份有限公司 异喹啉酮的固体形式、其制备方法、包含其的组合物及其使用方法
WO2017161116A1 (en) 2016-03-17 2017-09-21 Infinity Pharmaceuticals, Inc. Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as pi3k kinase inhibitors
US10919914B2 (en) 2016-06-08 2021-02-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
EP3740468B1 (en) * 2018-01-20 2025-12-31 Sunshine Lake Pharma Co., Ltd. Substituted Aminopyrimidine Compounds and Methods of Use
CN108516976B (zh) * 2018-04-27 2020-07-03 四川大学华西医院 一种7-脱氮嘌呤衍生物及其四元环超分子结构
WO2020058072A1 (en) * 2018-09-18 2020-03-26 Société des Produits Nestlé S.A. Src inhibitor compounds for skeletal muscle modulation, methods and uses thereof
WO2022017371A1 (zh) * 2020-07-21 2022-01-27 中国医药研究开发中心有限公司 具有磷脂酰肌醇3-激酶δ和γ的双重抑制剂活性的杂环化合物及其医药用途

Family Cites Families (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1204826B (it) 1986-03-04 1989-03-10 Chiesi Farma Spa Composizioni farmaceutiche per inalazione
GB9501841D0 (en) 1995-01-31 1995-03-22 Co Ordinated Drug Dev Improvements in and relating to carrier particles for use in dry powder inhalers
CN1150895C (zh) 1998-11-13 2004-05-26 杰格研究股份公司 用于吸入给药的干粉
DK1140938T3 (da) 1999-01-11 2003-12-22 Univ Princeton Højaffinitetsinhibitorer for målvalidering og anvendelser heraf
PT1158958E (pt) 1999-03-05 2007-08-13 Chiesi Farma Spa ''composições farmacêuticas em pó, melhoradas, para inalação''
PE20011227A1 (es) 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
US6667300B2 (en) 2000-04-25 2003-12-23 Icos Corporation Inhibitors of human phosphatidylinositol 3-kinase delta
DE60144277D1 (de) 2000-04-25 2011-05-05 Icos Corp Hemmer der menschlichen phosphatidyl-inositol-3-kinase delta
AU5261001A (en) 2000-04-27 2001-11-12 Imperial Cancer Research Technology Ltd Condensed heteroaryl derivatives
US6608053B2 (en) 2000-04-27 2003-08-19 Yamanouchi Pharmaceutical Co., Ltd. Fused heteroaryl derivatives
EP1217000A1 (en) 2000-12-23 2002-06-26 Aventis Pharma Deutschland GmbH Inhibitors of factor Xa and factor VIIa
WO2003006628A2 (en) 2001-07-13 2003-01-23 Virtual Drug Development, Inc. Nad synthetase inhibitors and uses thereof
AU2002317377A1 (en) 2001-07-20 2003-03-03 Cancer Research Technology Limited Biphenyl apurinic/apyrimidinic site endonuclease inhibitors to treat cancer
WO2004037176A2 (en) 2002-10-21 2004-05-06 Bristol-Myers Squibb Company Quinazolinones and derivatives thereof as factor xa inhibitors
JP4736043B2 (ja) 2003-03-14 2011-07-27 小野薬品工業株式会社 含窒素複素環誘導体およびそれらを有効成分とする薬剤
US7122557B2 (en) 2003-03-18 2006-10-17 Bristol-Myers Squibb Company Sulfonyl-amidino-containing and tetrahydropyrimidino-containing compounds as factor Xa inhibitors
JP2007524605A (ja) 2003-04-03 2007-08-30 ピーディーエル バイオファーマ，インコーポレイティド インテグリンα５β１のインヒビターおよび組織顆粒化の制御のためのそれらの使用
US7429596B2 (en) 2003-06-20 2008-09-30 The Regents Of The University Of California 1H-pyrrolo [2,3-D] pyrimidine derivatives and methods of use thereof
GB0316341D0 (en) 2003-07-11 2003-08-13 Glaxo Group Ltd Pharmaceutical formulations
JPWO2005012221A1 (ja) 2003-08-04 2006-09-14 小野薬品工業株式会社 ジフェニルエーテル化合物、その製造方法および用途
US20050054614A1 (en) 2003-08-14 2005-03-10 Diacovo Thomas G. Methods of inhibiting leukocyte accumulation
US20050043239A1 (en) 2003-08-14 2005-02-24 Jason Douangpanya Methods of inhibiting immune responses stimulated by an endogenous factor
GB0326632D0 (en) 2003-11-14 2003-12-17 Jagotec Ag Dry powder formulations
CA2552664A1 (en) 2004-01-08 2005-07-28 Michigan State University Methods for treating and preventing hypertension and hypertension-related disorders
EP1750714A1 (en) 2004-05-13 2007-02-14 Vanderbilt University Phosphoinositide 3-kinase delta selective inhibitors for inhibiting angiogenesis
LT2612862T (lt) 2004-05-13 2017-01-25 Icos Corporation Chinazolinonai kaip žmogaus fosfatidilinozitol-3-kinazės delta inhibitoriai
WO2005117889A1 (en) 2004-05-25 2005-12-15 Icos Corporation Methods for treating and/or preventing aberrant proliferation of hematopoietic
JP2008501707A (ja) 2004-06-04 2008-01-24 アイコス、コーポレーション マスト細胞障害を処置するための方法
AU2005283326B2 (en) 2004-09-13 2011-07-21 Ono Pharmaceutical Co., Ltd. Nitrogenous heterocyclic derivative and medicine containing the same as an active ingredient
GB0425758D0 (en) 2004-11-23 2004-12-22 Vectura Ltd Preparation of pharmaceutical compositions
US20080287469A1 (en) 2005-02-17 2008-11-20 Diacovo Thomas G Phosphoinositide 3-Kinase Inhibitors for Inhibiting Leukocyte Accumulation
GB0525254D0 (en) 2005-12-12 2006-01-18 Jagotec Ag Powder compositions for inhalation
KR20150038395A (ko) * 2006-04-04 2015-04-08 더 리젠트스 오브 더 유니이버시티 오브 캘리포니아 키나제 길항물질
SI2004654T1 (sl) * 2006-04-04 2013-11-29 The Regents Of The University Of California Pirazolopirimidinski derivati za uporabo kot kinazni antagonisti
EP2032605A2 (en) 2006-05-24 2009-03-11 Bayer Schering Pharma Aktiengesellschaft HIGH AFFINITY HUMAN AND HUMANIZED ANTI-alpha5ß1 INTEGRIN FUNCTION BLOCKING ANTIBODIES WITH REDUCED IMMUNOGENICITY
CA2655720A1 (en) 2006-06-29 2008-01-10 Schering Corporation Substituted bicyclic and tricyclic thrombin receptor antagonists
GB0622818D0 (en) 2006-11-15 2006-12-27 Jagotec Ag Improvements in or relating to organic compounds
CA2668744C (en) 2006-11-17 2015-09-15 Queen's University At Kingston Compounds and methods for treating protein folding disorders
US20090035306A1 (en) 2006-11-29 2009-02-05 Kalypsys, Inc. Quinazolinone modulators of tgr5
US8338437B2 (en) 2007-02-28 2012-12-25 Methylgene Inc. Amines as small molecule inhibitors
EP2155753A1 (en) * 2007-05-09 2010-02-24 Novartis Ag Substituted imidazopyridazines as pi3k lipid kinase inhibitors
WO2008140750A1 (en) 2007-05-10 2008-11-20 Hydra Biosciences Inc. Compounds for modulating trpv3 function
BRPI0906473A8 (pt) 2008-01-04 2016-02-10 Intellikine Inc Certas entidades químicas, composições e métodos
WO2010036380A1 (en) * 2008-09-26 2010-04-01 Intellikine, Inc. Heterocyclic kinase inhibitors
US20110269779A1 (en) 2008-11-18 2011-11-03 Intellikine, Inc. Methods and compositions for treatment of ophthalmic conditions
EP2365810A2 (en) 2008-12-04 2011-09-21 The U.S.A. As Represented By The Secretary, Department Of Health And Human Services Phosphatidylinositol-3-kinase p110 delta-targeted drugs in the treatment of cns disorders
EP2379505A4 (en) 2008-12-05 2012-10-17 Designmedix Inc MODIFIED CHLOROQUINE WITH SINGLE RING UNIT OR CONDENSED RING UNIT
US20110135655A1 (en) * 2009-01-13 2011-06-09 PHILADELPHIA HEALTH AND EDUCATION CORPORATION d/b/a Drexel University College of Medicine; Role of PI3K p110 delta Signaling in Retroviral Infection and Replication
AU2010229968A1 (en) * 2009-03-24 2011-10-13 Gilead Calistoga Llc Atropisomers of2-purinyl-3-tolyl-quinazolinone derivatives and methods of use
RU2012104214A (ru) 2009-08-05 2013-09-10 Верситек Лимитед Противовирусные соединения и способы их получения и применения
GB0918249D0 (en) 2009-10-19 2009-12-02 Respivert Ltd Compounds
WO2012041717A1 (en) 2010-09-30 2012-04-05 Chiesi Farmaceutici S.P.A. Use of magnesium stearate in dry powder formulations for inhalation
UY33337A (es) 2010-10-18 2011-10-31 Respivert Ltd DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS
NZ627963A (en) 2012-03-13 2015-08-28 Respivert Ltd Dry powder pharmaceutical formulations for inhalation of a compound that inhibits pi3 kinase

Also Published As

Publication number Publication date
PT2491037E (pt) 2014-07-11
ES2477270T3 (es) 2014-07-16
US20120208799A1 (en) 2012-08-16
US9834560B2 (en) 2017-12-05
KR101770616B1 (ko) 2017-08-23
JP2013508334A (ja) 2013-03-07
SI2491037T1 (sl) 2014-08-29
UA108743C2 (uk) 2015-06-10
ME02064B (me) 2015-05-20
CA2777902C (en) 2018-03-06
MX2012004525A (es) 2012-05-29
WO2011048111A1 (en) 2011-04-28
NZ599162A (en) 2013-08-30
AR078674A1 (es) 2011-11-23
RS53385B (sr) 2014-10-31
MY164731A (en) 2018-01-30
US9321773B2 (en) 2016-04-26
AU2010309832A1 (en) 2012-04-19
EP2491037A1 (en) 2012-08-29
NZ609147A (en) 2014-03-28
CN102712645A (zh) 2012-10-03
US20140249164A1 (en) 2014-09-04
IL219248A0 (en) 2012-06-28
AU2010309832B2 (en) 2014-01-30
HRP20140599T1 (hr) 2014-09-12
EA020330B1 (ru) 2014-10-30
GB0918249D0 (en) 2009-12-02
US20160264583A1 (en) 2016-09-15
CY1116057T1 (el) 2017-02-08
HK1173728A1 (en) 2013-05-24
PE20121390A1 (es) 2012-10-15
CA2777902A1 (en) 2011-04-28
EP2491037B1 (en) 2014-04-30
TW201124418A (en) 2011-07-16
NI201300035A (es) 2013-06-04
KR20120114225A (ko) 2012-10-16
PH12012500620A1 (en) 2015-03-20
IL219248A (en) 2015-02-26
EA020330B3 (ru) 2015-07-30
SMT201400086B (it) 2014-09-08
ECSP12011805A (es) 2012-06-29
BR112012009214A2 (pt) 2016-08-16
US20180118754A1 (en) 2018-05-03
EA201270575A1 (ru) 2012-09-28
ZA201203662B (en) 2013-10-30
NI201200061A (es) 2013-05-15
CR20120264A (es) 2013-01-25
CL2012000981A1 (es) 2012-08-31
DK2491037T3 (da) 2014-07-21
CN102712645B (zh) 2015-10-21
TWI478923B (zh) 2015-04-01
JP5889792B2 (ja) 2016-03-22
US8741909B2 (en) 2014-06-03

Similar Documents

Publication Publication Date Title
PT2491037E (pt) Derivados de quinazolin-4(3h)-ona utilizados como inibidores de pi3-cinases
IL225212A0 (en) History of quinazoline–4 (h3)–ones used as pi3 kinase inhibitors
EP2167092A4 (en) QUINAZOLINE DERIVATIVES AS INHIBITORS OF PI3 KINASE
IL220212A0 (en) Aminopyrimidine kinase inhibitors
EP2211615A4 (en) PYRIDOSULFONAMIDE DERIVATIVES AS PI3 KINASE INHIBITORS
EP2217590A4 (en) Pyridopyrimidine derivatives as PI3-kinase inhibitors
IL202018A0 (en) Quinoline derivatives as pi3 kinase inhibitors
MX315904B (es) Inhibidores de fosfoinosituro-3 cinasa.
IL218555A0 (en) Pi3 kinase inhibitors and uses thereof
ZA201100344B (en) Pyrimidine derivatives as kinase inhibitors
IL218617A (en) Derivatives of pyridinylimidazolone for inhibition of 3pi kinases
IL219646A0 (en) Novelnaphthyridine derivatives and the use thereof as kinase inhibitors
EP2173354A4 (en) CHINOXALIN DERIVATIVES AS PI3 KINASE INHIBITORS
PL2419427T3 (pl) Dwupierścieniowe pochodne heterocykliczne związków jako kinazy tyrozynowe FGFR do terapeutycznego stosowania
ZA201204246B (en) Kinase inhibitors
ZA201203842B (en) Kinase inhibitors
SMT201700158T1 (it) Derivati benzimidazolici come inibitori della chinasi pi3
ZA201108622B (en) Pyrazolopyrimidines and related heterocycles as kinase inhibitors
PL2231642T3 (pl) Pirymidyny jako inhibitory kinazy
IL212755A0 (en) Pyrazinopyrazines and derivatives as kinase inhibitors
EP2478361A4 (en) CONJUGATES AND INHIBITORS OF PROTEIN KINASE
IL219872A0 (en) Quinazoline derivatives
GB0907120D0 (en) Inhibitors of IKK-ß serine-threonine protein kinase
GB0914726D0 (en) Kinase inhibitors